TTRX (Turn Therapeutics Inc. Common Stock) Stock Analysis - News
Turn Therapeutics Inc. Common Stock (TTRX) is a publicly traded the market company. As of May 21, 2026, TTRX trades at $4.69 with a market cap of $145.96M and a P/E ratio of -40.28. TTRX moved +0.00% today. Year to date, TTRX is +0.63%; over the trailing twelve months it is flat. Its 52-week range spans $2.57 to $26.50. Rallies surfaces TTRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in TTRX news today?
Turn Therapeutics Secures $25M Growth Facility, Medline Deal Targets Late-2026 Revenue: Turn Therapeutics obtained a $25M venture debt facility, providing a 42-month term and extending cash runway through end-2027 with a $7M initial tranche. The company reported a $3.19M net loss on $5.08M cash, appointed Dr. Robert Redfield and signed a global Medline license to start revenue in late-2026.
Chaudhary Zuraiz bought 2.50K (~$8.75K) on Dec 12, 2025.
GOLDEN ARTHUR F bought 9.87K (~$33.95K) on Nov 24, 2025.
GOLDEN ARTHUR F bought 20.53K (~$58.93K) on Nov 21, 2025.
TTRX Analyst Consensus
TTRX analyst coverage data. Average price target: $0.00.
Common questions about TTRX
What changed in TTRX news today?
Turn Therapeutics Secures $25M Growth Facility, Medline Deal Targets Late-2026 Revenue: Turn Therapeutics obtained a $25M venture debt facility, providing a 42-month term and extending cash runway through end-2027 with a $7M initial tranche. The company reported a $3.19M net loss on $5.08M cash, appointed Dr. Robert Redfield and signed a global Medline license to start revenue in late-2026.
Does Rallies summarize TTRX news?
Yes. Rallies summarizes TTRX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is TTRX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for TTRX. It does not provide personalized investment advice.
